<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200429047236N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-12</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of topical administration and infusion of tranexamic acid on the rate of bleeding in children with non-cyanotic heart disease after open heart surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of topical and continuous infusion of Tranexamic Acid administration on bleeding in pediatric with non-cyanotic congenital heart disease</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-10-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47550</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Based on the census and random allocation, the samples were divided into two groups of 25 people. This randomization was performed using Random Allocation software 2.0, in which patients were assigned to one of two groups based on the number of entries in the study. This is done by a nurse outside the research team and the groups are identified as A and B. The unit of randomization is individual. Also, randomization in two groups is Balanced Block Randomization, ie the number of people in two groups is equal, Blinding description: After obtaining informed consent from the patient's guardian (the study was performed on children), the study was one- blind side, in which only participants or patients were uninformed to the study groups, and the main staff and researchers and other colleagues who They were involved in this project, they were aware of the choice of group type, it was done.</study_design>
      <phase>2</phase>
      <hc_freetext>Diseases of Atrial and Ventricular septum defect.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:The first group of interventions includes patients undergoing continuous infusion of 50 mg per kg tranexamic acid from induction to sternum closure. Intervention 2: Intervention group:The second group of interventions are patients receiving topical administration of 50 mg per kg tranexamic acid, which has reached 20 ml with a normal saline solution. Before closing the sternum, it is poured into the pericardium and the patient's middle mediastan tubes are clamped for 20 minutes. (The nurse uses a sterile syringe to draw the drug into the syringe and then to a concentration of 20 ml).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Some of the data related to the result is available.

When:
6 months after publishing the results

To whom:
All of the searchers

Conditions:
There are no special conditions

Where to obtain:
Executor or person in charge of the project

How to obtain:
Contact the executor or the person in charge of the project and up to one week after the contact (contact information is mentioned.)

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Minoo Montazeri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.24 , Baharestan 9th, North Janat abad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1478777887</zip>
        <telephone>+98 21 4481 3915</telephone>
        <email>minomah17@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamid Bigdelian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 308,Notrth Alley 1th, Alikhani Ave, Mehr Ave</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1478777887</zip>
        <telephone>+98 31 3260 3145</telephone>
        <email>hamidbigdelian@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children under 14 kg and over 6 kg
For the first time, they undergo cardiac surgery to correct the aforementioned non-cyanotic diseases with cardiac bypass.
Clamp aortic time between 60 to 90 minutes
CPB(cardio pulmonary bypass) time between 60 to 180 minute
Hemoglobin(HB) above 8 mg per deciliter before surgery
Minimum age 1 month and maximum age 9 years</inclusion_criteria>
      <agemin>1 month</agemin>
      <agemax>9 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>hemoglobin below 8 mg per deciliter before surgery
Active non-revolutionary disease affecting postoperative recovery such as severe coagulation disorder, hemophilia and.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I51.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cardiac septal defect, acquired</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:The first group of interventions includes patients undergoing continuous infusion of 50 mg per kg tranexamic acid from induction to sternum closure.</i_keyword>
      <i_keyword>Intervention group:The second group of interventions are patients receiving topical administration of 50 mg per kg tranexamic acid, which has reached 20 ml with a normal saline solution. Before closing the sternum, it is poured into the pericardium and the patient's middle mediastan tubes are clamped for 20 minutes. (The nurse uses a sterile syringe to draw the drug into the syringe and then to a concentration of 20 ml).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bleeding rate in children with congenital non-cyanotic heart disease after open heart surgery. Timepoint: Upon arrival at the intensive care unit, 6, 12, 24 and 48 hours after surgery. Method of measurement: To determine the amount of bleeding, hemoglobin is measured based on arterial sampling and sent to a laboratory to measure and record arterial blood gases, and the unit is geram per deciliter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Time of intubation. Timepoint: Upon arrival at the intensive care unit, 6, 12, 24 and 48 hours after surgery. Method of measurement: Hours and minute.</sec_outcome>
      <sec_outcome>Intensive care unit stay. Timepoint: Upon arrival at the intensive care unit, 6, 12, 24 and 48 hours after surgery. Method of measurement: Time and minute.</sec_outcome>
      <sec_outcome>Mount of derenage. Timepoint: Upon arrival at the intensive care unit, 6, 12, 24 and 48 hours after surgery. Method of measurement: According to cc.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-09</approval_date>
        <contact_name>ethics committe of Isfahan university of medical sciences</contact_name>
        <contact_address>No. 24, Baharestan 9th, Northen Janat Abad Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
